Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference
Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference
SAN DIEGO, May 30, 2024 — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company will be presenting a poster at the American Society for Microbiology (ASM) Microbe 2024 conference to be held June 13-17, 2024 at the Georgia World Congress Center in Atlanta, Georgia.
聖地亞哥，2024年5月30日——使用其專有Cloudbreak的生物技術公司Cidara Therapeutics, Inc.（納斯達克股票代碼：CDTX） 開發藥物-FC偶聯物（DFC）免疫療法的平台今天宣佈，該公司將在2024年6月13日至17日在佐治亞州亞特蘭大的喬治亞世界會議中心舉行的美國微生物學會（ASM）微生物2024年會議上展示海報。
Presentation details are summarized below:
演示詳情總結如下：
Abstract Title: Comparison of Different Allometric Scaling Approaches to Project Human Pharmacokinetics (PK) of CD388, a Novel Drug-Fc Conjugate, in Development for Influenza Prevention
Presenter: Voon Ong, Ph.D.
Session Title: AAR07 Saturday Antimicrobial Pharmacokinetics and Pharmacodynamics
Presentation Location: Exhibit Hall
Date and Time: Saturday, June 15, 2024, 10:00 AM -5:00 PM ET
Poster Board Number: AAR-SATURDAY–494
摘要標題：比較爲預防流感而開發的新型藥物-Fc偶聯物 CD388 的人體藥代動力學（PK）的不同異速測量方法
演講者：王文博士
會議標題：AAR07 星期六抗菌藥代動力學和藥效學
演示地點：展廳
日期和時間：美國東部時間 2024 年 6 月 15 日星期六上午 10:00-下午 5:00
海報板編號：AAR-SATURDAY—494
About Cidara Therapeutics
Cidara is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
關於 Cidara Therapeu
Cidara正在開發免疫療法，旨在幫助提高面臨嚴重疾病的患者的護理標準。該公司的產品組合包括旨在改變現有治療和預防模式的新方法，包括來自其專有Cloudbreak的DFC 針對腫瘤、病毒和自身免疫疾病的平台。Cidara 總部位於加利福尼亞州聖地亞哥。欲了解更多信息，請訪問 www.cidara.com。
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
投資者聯繫人：
布萊恩·裏奇
生命科學顧問
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
媒體聯繫人：
邁克爾·菲茨休
LifeSci
mfitzhugh@lifescicomms.com
譯文內容由第三人軟體翻譯。